C-ETLXFission Pharma
DRP1-FIS1 inhibitors, small molecules, mitochondrial protection
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ETLX
C-ETLXC-ETLXDRP1-FIS1 inhibitors, small molecules, mitochondrial protection
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Luis Rios - Longevity Biotech Fellow at Longevity Biotech Fellowship | The Org Platform Enrich Pricing Log in Sign up Longevity Biotech Fellowship Luis Rios Unverified LR Luis Rios Longevity Biotech Fellow Contact Luis Rios, PhD is the Founder and CEO of Fission Pharma, a start-up focused on revolutionizing the treatment of inflammatory diseases. With a background in chemical and systems biology, Luis serves as a Longevity Biotech Fellow at Longevity Biotech Fellowship, Director of Drug Discovery at ImmuneAGE Pharma, Consultant at Longitude Capital, and Scientific Advisor at Healthspan Capit … person is not in any offices Related people Brandon Sassouni Longevity Biotech Fellowship Julija Rabcuka Longevity Biotech Fellowship Mack Lorden Longevity Biotech Fellowship Saba Nateghi Longevity Biotech Fellowship Daniel Shur Longevity Biotech Fellowship CS Chen-Yang Su Longevity Biotech Fellowship View more Company About Contact Blog Business Solutions Trust Pricing Directory Companies People Features Employer Branding Professional Networking Job Discovery Social © 2026
Stanford Chemical and Systems Biology | Stanford Medicine » Luis Rios Donate Toggle navigation Menu Apply Department Faculty Ph.D. Program Postdoctoral Program Publications Alumni Alumni Profile Luis Rios Graduate Student Mochly-Rosen / CSB 2017-2022 Employer: Fission Pharma Position: Founder and CEO LinkedIn Profile » « Back To Alumni Explore: Apply Department Faculty Ph.D. Program Postdoctoral Program Publications Alumni Connect: StanfordMed Pulse Facebook LinkedIn Twitter YouTube Contact: CCSR Building James H. Clark Center Lokey Stem Cell Research div" data-cycle-pager="#
VDP-123 [Assessment] Fission Pharma - Proposals - Governance Forum | VitaDAO = 40rem)" rel="stylesheet" data-target="desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-ai_desktop" /> = 40rem)" rel="stylesheet" data-target="poll_desktop" /> = 40rem)" rel="stylesheet" data-target="desktop_theme" data-theme-id="3" data-theme-name="sam's simple theme"/> Governance Forum | VitaDAO VDP-123 [Assessment] Fission Pharma Proposals Paolo September 18, 2023, 6:28pm 1 One-liner : Fission Pharma is a pre-seed AI-driven drug discovery platform with a lead program developing a protein-protein i … : Brain penetrant DRP1-FIS1 inhibitors, compositions and uses thereof. · Patent application filing planned for 2024, before Case Western studies. Second Group : Orally available but peripherally restricted DRP1-FIS1 inhibitors for peripheral indications, compositions and uses thereof. · Patent application filing planned for 2025, just before IND-enabling studies. Third Group : Low penetrance DRP1-FIS1 inhibitors for gut and eye restricted delivery, compositions and uses there … rs for gut and eye restricted delivery, compositions and uses thereof. · Patent application filing planned for 2025, just before IND-enabling studies. In silico discovery method (trade secret). · Using GPU-accelerated empirical docking to train a diffusion model and accurately screen for compounds at non-traditional binding sites (sites that are poorly represented in the training data sets used to train AI models). Experimental Plan Immagine che contiene testo, schermata, Car … advisor at Healthspan Capital, and entrepreneur in residence at the Centenarian Fund. Co-founder- Pending funding for full-time hire. Ideal candidate selected. Justin Tso, MA- Operations at Fission Pharma. Justin oversees funding opportunities, grant writing, deck building, and networking at events. He has venture experience as a venture fellow at RTW investments, Columbia Technology Ventures, and Nucleate. MA from Columbia University in Biotechnology. Bachelors in business a … . They come at the right time, because we are about to release an update of the proposal with SAFE terms ! That said, concerning the royalty terms , they could actually be much better than what it looks at first sight. I have checked this numbers on a simplified model that I have developed and crossed-checked with other VitaDAO colleagues, includ
Cerebrum DAO Projects - Protein to Protein Interaction Drug - Fission Bio Researchers Projects Community Dashboard Cognition Cortex App Blog Get NEURON This website uses cookies to improve your browsing experience. Please read our Privacy Policy for more information on what data we gather and how it is used. Preferences Deny all cookies Allow all cookies Privacy Preference Center When you visit websites, they may store or retrieve data in your browser. This storage is often necessary for the basic functionality of the website. The storage may be used for marketing, analytics, and personalizati … Luis Rios Co-Founder & Principal Investigator Brian Magierski CEO GET MITY Apply for Funding IP-Token IP-Token Spinout Spinout Funding $400,000 Initiated April 23, 2024 Organisation Stanford University GET MITY Apply for Funding Project Details MITY Contract Address (Ethereum): 0xd07eA8776e52c1b67dcA6ffBC3F659Fc9fbe4113 Background Fission Bio is a pre-seed drug discovery platform focused on developing innovative treatments for chronic inflammation and neurodegenerative d … g Patent Status Not Filed Yet Project Links Pitch Deck On-chain Vote Governance Proposal Pitch Deck On-chain Vote Governance Proposal Get MITY Project Updates January 18th, 2025 NEURON-Fission is tokenized and raises $188K+ November 18th, 2024 IP-NFT funded by token holders November 11th, 2024 CerebrumDAO decides to solely fund the project May 1st, 2024 $NEURON token holders decide to co-fund Fission Pharma with VitaDAO April 23rd, 2024 Proposal to co-fund project with Vi … DAO token holders decide to provide €75,000 in funding to AT October 21st, 2024 Proposal to participate in Arctic Therapeutics (AT) financing round March 27th, 2025 NEURON-FIDEL is successfully tokenized September 2nd, 2024 Project Transfidelity raises 76.461 ETH on Molecule Catalyst platform August 13th, 2024 Proposal approved for funding by $NEURON token holders August 6th, 2024 Proposal to co-fund project with VitaDAO November 26th, 2024 NEURON-CLAW is tokenized and raises … ved via IP-NFT by $NEURON token holders October 4th, 2024 The Percepta® funding application is submitted January 18th, 2025 NEURON-Fission is tokenized and raises $188K+ November 18th, 2024 IP-NFT funded by token holders November 11th, 2024 CerebrumDAO decides to solely fund the project May 1st, 2024 $NEURON token holders decide to co-fund Fissio
VDP-103 [Funding]: Mutation-Specific Codon Suppression for Aging and Longevity - Active Proposals - Governance Forum | VitaDAO = 40rem)" rel="stylesheet" data-target="desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-ai_desktop" /> = 40rem)" rel="stylesheet" data-target="poll_desktop" /> = 40rem)" rel="stylesheet" data-target="desktop_theme" data-theme-id="3" data-theme-name="sam's simple theme"/> Governance Forum | VitaDAO VDP-103 [Funding]: Mutation-Specific Codon Suppression for Aging and Longevity Proposals Active Proposals Paolo May 28, 2023, 11:42pm 1 One liner : a first- … : project kickoff meeting to be organized by PM after on-chain approval of the proposal. Phase 1 : Design & generate an arginine opal suppressor construct for use in an AAV9 vector. The rationale for AAV9 is that it is the most clinically validated AAV with the broadest tropism. Risk mitigation: after the in-vitro data with AAV there could be a decision point to consider different delivery modalities. We can design an arginine opal suppressor as an oligo that could be co … 2 and presentation of results in a dedicated meeting or at a quarterly review, proposal for next round of funding. Note, a provisional patent could be filed at this stage. Additional phases part of the plan, but not funded Phase 3 : In vivo testing of selected vectors/oligos in relevant age-related/lifespan models. In consultation with VitaDAO, the team would identify relevant disease and lifespan models to test selected vectors/oligos to confirm the efficacy and evaluate th … a VC-backed company, raising $80M from prominent investors and securing a $3.2M award from the CF Foundation. With a strong background in research and development, Michael Torres has held the position of VP of R&D at ReCode Therapeutics, Inc., where they directed cross-functional teams, managed therapeutic programs, and facilitated the preclinical development of novel tRNA/mRNA LNP drug products. Michael Torres has also contributed significantly to the field through their … companies. In addition, he helped in launching Hibiscus’ Mayflower BioVentures fund, which spearheaded laboratory-stage therapeutic assets from the Mayo Clinic into companies. He is a professor at Johns Hopkins, teaching finance and how to start a biotechnology company. Finally, he runs a Biotechnology based consulting agency, BioVisors, and vol
VitaDAO Letter: From Dubai to London - VitaDAO’s Substack VitaDAO’s Substack Subscribe Sign in VitaDAO Letter: From Dubai to London VitaDAO May 15, 2024 1 Share Hey there, Vitalians! Welcome to the monthly VitaDAO Newsletter, a recap of all that’s happened and is happening within the VitaDAO community. Spoiler alert: as always, a lot was going on last month! VitaDAO members have been busy coordinating a DeSci Summit in Dubai, sponsoring DeSci London, passing two new governance proposals, and launching $VITA on Base. In this newsletter, you’ll find recaps of past important events, updates on vo … is a decentralized organization of individuals from across the globe working to fund early-stage longevity research. You might be wondering, “So, what is the point of having a $VITA token ?” $VITA is a governance token that allows members to contribute to the DAO’s decision-making. By allowing the community to vote on which research projects to fund, VitaDAO leverages the collective knowledge of its community to support projects that might not otherwise be funded. If you’re i … building project worth $250k and proposed as VDP-143 on March 15th, 2024. This proposal approved a research plan expansion to be covered with $83,333 in co-funding from Cerebrum DAO in exchange for a share of the resulting IP-NFT. The total approved project budget is $333,333. VDP-144 (The Longevist Annual Review Proposal) : The Longevist is a quarterly issued preprint overlay journal where key opinion leaders in both academia and industry vote on chain on the top preprints. … leaders in both academia and industry vote on chain on the top preprints. This proposal approved a budget of 25,000 $VITA for curator compensation and 15,000 $VITA + $35,000 USDC for operations for the Longevist in 2024. The VDP also outlined Longevist achievements thus far and five objectives for the future including: Expanding and developing a curator network Strengthening outreach and engagement Growing an academic reader community Developing and distributing educational … ibuting educational material for the general public Hosting an annual Longevist award ceremony 💪Exercise Your Right to Vote Visit VitaDAO’s governance hub ( Discourse ) to engage with, vote on, and discuss proposals before they are moved to Snapshot. Together, we can shape the future of VitaDAO and accelerate decentralized science. 💸Refer a Pro
VDP-143 [Funding] Fission Pharma - Revised - Proposals - Governance Forum | VitaDAO = 40rem)" rel="stylesheet" data-target="desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-ai_desktop" /> = 40rem)" rel="stylesheet" data-target="poll_desktop" /> = 40rem)" rel="stylesheet" data-target="desktop_theme" data-theme-id="3" data-theme-name="sam's simple theme"/> Governance Forum | VitaDAO VDP-143 [Funding] Fission Pharma - Revised Proposals Paolo March 13, 2024, 5:49am 1 One-liner : Fission Pharma is developing a protein-protein interaction inhibitor that cuts the link between chronic … ongevity Dealflow WG Team Senior reviewers : the same reviewers as the previous proposal, including two entrepreneurs, an executive, a VC, and a professor, provided a review update. Shepherd : Paolo Binetti, Ryan Spangler Squad members : Eleanor Davies Sourced by : Paolo Binetti, Ryan Spangler Project Team Principal Investigator: Luis Rios, PhD VitaDAO Entrepreneur In Residence/Project Manager: Anthony Schwartz, Ph.D. Simple Summary Fission Pharma is creating the first drug-l … .4 KB The activities are described in detail below for phase 1, covered by this proposal, and phase 2, to be covered by the follow-up IPT funding. Phase 1 (IP Building Round): In Silico Screen for DRP1-FIS1 inhibitors We are screening the Enamine REAL library (48 billion compounds) that bind the DRP1-FIS1 protein-protein interaction groove. These hits are filtered for drug-like properties and problematic functional groups are removed with a series of filters (PAINS, Brenk, CY … ase 2 (IPT Pre-Seed): Lead selection and In-vivo efficacy (not included in this proposal) DMPK and Toxicity (Selvita) Top 10 hits are screened for solubility, membrane permeability, liver metabolism, and hepatotoxicity. Results inform the hit to lead optimization design effort. IP is filed on high performing scaffolds. In vitro efficacy in ALS, HD, and AD models (by Xin Qi at Case Western) Disease modifying activity will be confirmed in lead candidates. AD, ALS, and HD patien … and AD). IP Building Round Budget Breakdown The total budget requested for this proposal is $333k, broken down as follows: Budget 1 465×281 49.2 KB Budget 2 465×288 47.8 KB Financing and VitaDAO funding terms IP Building Round: This phase focuses on identifying promising leads and filing provisional patents for NCEs (New Chemical Entities). The p